IDORSIA AG SF-,05/ CH0363463438 /
- - | Chg. - | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
-EUR | - | - Turnover: - |
-Bid Size: - | -Ask Size: - | -EUR | - | - |
GlobeNewswire
28/02
Idorsia and Viatris enter into a significant global research and development collaboration
GlobeNewswire
03/11/2023
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at th...
GlobeNewswire
08/02/2022
Idorsia announces financial results for 2021 – 2022 to be a transformative year – Sustainable profit...
GlobeNewswire
26/01/2022
Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and ...
GlobeNewswire
10/01/2022
Idorsia presents at the 40th J.P. Morgan Healthcare Conference – Ready for first product launches – ...
GlobeNewswire
10/01/2022
Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults ...
GlobeNewswire
27/07/2021
Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a f...
GlobeNewswire
20/07/2021
Invitation to Idorsia's half year financial results 2021 webcast and conference call
GlobeNewswire
28/06/2021
Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardi...
GlobeNewswire
09/06/2021
Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021
GlobeNewswire
22/04/2021
Idorsia announces financial results for the first quarter 2021 – substantial progress made across th...
GlobeNewswire
10/03/2021
FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult...
GlobeNewswire
11/01/2021
Idorsia to debut at the 39th J.P. Morgan Healthcare Conference – Major catalysts expected in the nea...
GlobeNewswire
23/11/2020
Idorsia announces positive results of the two Japanese registration studies with clazosentan
GlobeNewswire
02/09/2020
Janssen announces the presentation of additional ponesimod data at MSVirtual2020: 8th Joint ACTRIMS-...
GlobeNewswire
31/08/2020
Idorsia selects Syneos Health as commercialization partner to launch daridorexant in the United Stat...
GlobeNewswire
06/07/2020
Idorsia announces positive results in the second Phase 3 study of daridorexant
GlobeNewswire
03/05/2019
Idorsia holds its second Annual General Meeting of Shareholders - All Board proposals approved